Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation.
NK cell degranulation
SARS-CoV-2
antibody
binding
infected cell
Journal
Cytometry. Part A : the journal of the International Society for Analytical Cytology
ISSN: 1552-4930
Titre abrégé: Cytometry A
Pays: United States
ID NLM: 101235694
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
08
02
2022
received:
02
12
2021
accepted:
15
03
2022
pubmed:
19
3
2022
medline:
3
6
2022
entrez:
18
3
2022
Statut:
ppublish
Résumé
Since the beginning of the SARS-CoV-2 pandemic, antibody responses and antibody effector functions targeting SARS-CoV-2-infected cells have been understudied. Consequently, the role of these types of antibodies in SARS-CoV-2 disease (COVID-19) and immunity is still undetermined. To provide tools to study these responses, we used plasma from SARS-CoV-2-infected individuals (n = 50) and SARS-CoV-2 naive healthy controls (n = 20) to develop four specific and reproducible flow cytometry-based assays: (i) two assessing antibody binding to, and antibody-mediated NK cell degranulation against, SARS-CoV-2-infected cells and (ii) two assessing antibody binding to, and antibody-mediated NK cell degranulation against, SARS-CoV-2 Spike-transfected cells. All four assays demonstrated the ability to detect the presence of these functional antibody responses in a specific and reproducible manner. Interestingly, we found weak to moderate correlations between the four assays (Spearman rho ranged from 0.50 to 0.74), suggesting limited overlap in the responses captured by the individual assays. Lastly, while we initially developed each assay with multiple dilutions in an effort to capture the full relationship between antibody titers and assay outcome, we explored the relationship between fewer antibody dilutions and the full dilution series for each assay to reduce assay costs and improve assay efficiency. We found high correlations between the full dilution series and fewer or single dilutions of plasma. Use of single or fewer sample dilutions to accurately determine the response rates and magnitudes of the responses allows for high-throughput use of these assays platforms to facilitate assessment of antibody responses elicited by SARS-CoV-2 infection and vaccination in large clinical studies.
Identifiants
pubmed: 35301794
doi: 10.1002/cyto.a.24552
pmc: PMC9087172
mid: NIHMS1790461
doi:
Substances chimiques
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
483-496Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068618
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201800004C
Pays : United States
Informations de copyright
© 2022 The Authors. Cytometry Part A published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.
Références
PLoS One. 2021 Mar 4;16(3):e0247640
pubmed: 33661923
Sci Immunol. 2021 Jul 15;6(61):
pubmed: 34266981
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
STAR Protoc. 2021 Dec 17;2(4):100851
pubmed: 34541555
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Cell Rep Med. 2021 Sep 21;2(9):100405
pubmed: 34485950
Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5
pubmed: 34688376
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2003 Jul 26;362(9380):263-70
pubmed: 12892955
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
Nat Commun. 2020 Nov 26;11(1):6013
pubmed: 33243994
Signal Transduct Target Ther. 2021 Sep 24;6(1):346
pubmed: 34561414
Elife. 2020 Jun 23;9:
pubmed: 32573433
J Virol. 2004 Jun;78(11):5913-22
pubmed: 15140989
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
Semin Immunol. 2018 Oct;39:102-110
pubmed: 29903548
Cell. 2021 Apr 1;184(7):1804-1820.e16
pubmed: 33691139
Virology. 2021 Jul;559:1-9
pubmed: 33774551
Cytometry A. 2022 Jun;101(6):483-496
pubmed: 35301794
Nat Commun. 2017 Jun 08;8:15711
pubmed: 28593989
Hum Pathol. 2003 Aug;34(8):743-8
pubmed: 14506633
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
J Immunol Methods. 2004 Nov;294(1-2):15-22
pubmed: 15604012
J Virol. 2011 Jul;85(14):7029-36
pubmed: 21543485
Br J Exp Pathol. 1986 Aug;67(4):581-6
pubmed: 3017399
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33211088
Nat Commun. 2021 Feb 15;12(1):1018
pubmed: 33589636
J Thorac Oncol. 2020 May;15(5):700-704
pubmed: 32114094
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
Lancet. 2003 May 24;361(9371):1773-8
pubmed: 12781536
Nat Rev Immunol. 2018 Jan;18(1):46-61
pubmed: 29063907
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272
pubmed: 29712861